Treatment
Cisplatin clinical trials
We’re tracking 487 recruiting studies that include Cisplatin, each written for real people, not researchers, below.
Recruiting studies
- NCT07662395RecruitingPhase 2/Phase 3
New drug plus chemo for advanced squamous lung cancer
This trial tests a new drug (SCTB41) combined with chemotherapy for people with advanced squamous non-small cell lung cancer who have not had any prior treatment. It aims to see if this combination works better than standard therapy.
Guangzhou, GuangdongAges 18 years+ - NCT07353294Enrolling by invitationPhase 1
Propranolol plus immunotherapy and chemo before bladder cancer surgery
This trial tests adding a blood pressure medication (propranolol) to a combination of immunotherapy (tislelizumab) and chemotherapy before surgery for bladder cancer that has spread to lymph nodes. It aims to see if this can help shrink the tumor before it is removed.
Guangzhou, GuangdongAges 18 years+ - NCT07312578Enrolling by invitationPhase 2
Targeted drugs plus chemo before surgery for esophageal cancer
This trial tests a combination of two targeted drugs (nimotuzumab and camrelizumab) plus standard chemotherapy before surgery for people with esophageal squamous cell carcinoma. The goal is to see if this approach helps shrink the tumor and improve outcomes.
Beijing, Beijing MunicipalityAges 18–70 - NCT06786780Enrolling by invitationPhase 2
Predicting chemoradiation response with cervical cancer organoids
This trial is studying whether lab-grown mini-tumors (called organoids) from your cervical cancer biopsy can predict how well chemoradiation will work. It aims to create a tool to help doctors choose the best treatment for each patient.
Chongqing, ChinaAges 18 years+ - NCT06281964Enrolling by invitationPhase 3
New pill for EGFR Exon 20 lung cancer
This study tests a new pill called PLB1004 for people whose lung cancer has a specific EGFR mutation (exon 20 insertion). It is for those who have not yet had any treatment for their advanced cancer.
Guangzhou, GuangzhouAges 18 years+ - NCT06048926Enrolling by invitation
Carrelizumab with chemoradiation for advanced esophageal cancer
This trial tests combining the immunotherapy drug carrelizumab with standard chemotherapy and radiation for people with advanced esophageal cancer that cannot be surgically removed. It aims to see if this combination can help shrink or control the tumor.
NanjingAges 18–75 - NCT04762459Enrolling by invitationPhase 3
Almonertinib after lung tumor surgery, with or without chemo
This study tests whether almonertinib taken after complete surgery can improve outcomes for people with stage II–IIIA non-small cell lung cancer (NSCLC) that has certain EGFR gene changes. It also compares almonertinib plus chemotherapy versus almonertinib alone to see which approach is safer and works better.
Beijing, Beijing MunicipalityAges 18–130
Common questions
- Are there clinical trials studying Cisplatin?
- Yes. Clin2 currently lists 487 recruiting studies that include Cisplatin, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Cisplatin trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Cisplatin an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Cisplatin or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.